Analyst Targets
- NVS (Novartis): Bank of America, Buy, $185 target; views pelacarsen as a contained setback with low-single-digit valuation downside
- NVO (Novo Nordisk): Morgan Stanley, Underweight; Morgan Stanley cited muted medium-term growth and semaglutide patent risk following the ZEUS result
- IONS (Ionis Pharmaceuticals): Citi, Buy, $100 target; analyst Eric Joseph sees less than 5% immediate downside from Lp(a)HORIZON
What Happened This Weekend
Two of cardiology’s most anticipated drug programs failed in full view of the field at the American Heart Association Scientific Sessions in Chicago. The direction was already known from earlier topline disclosures, but the full datasets presented Saturday, November 7, 2026 and published in the New England Journal of Medicine stripped away every remaining escape hatch.
Pelacarsen did not reduce the risk of major adverse cardiovascular events versus placebo in patients with preexisting cardiovascular disease and high Lp(a). The drug delivered about a 78% reduction in Lp(a) after 12 months, and the particle came down. The events did not.
At median follow-up of 4.7 years, MACE occurred in 12.3% of pelacarsen patients versus 12.1% on placebo. The hazard ratio for the primary endpoint was 1.02, and extended secondary analyses were, in Steven Nissen’s words, “essentially the same, neutral.”
In the subgroup with baseline Lp(a) of at least 90 mg/dL, event rates were identical at 12.3% in both arms. That was the last credible floor the bulls could stand on. It held nothing.
Novo Nordisk’s ZEUS result confirmed the same logic applied to inflammation. Ziltivekimab, an IL-6 inhibitor, did not reduce cardiovascular events in 6,376 patients with ASCVD, chronic kidney disease, and elevated hsCRP. MACE occurred in 17.6% on drug versus 17.7% on placebo, HR 0.99. Biology worked. Medicine did not.
What Each Company Loses
Novartis. Novartis reported on September 4, 2026 that pelacarsen missed the Lp(a)HORIZON primary endpoint, and it later communicated in October 2026 that it would discontinue the pelacarsen clinical development program for atherosclerotic cardiovascular disease. Only a single mid-stage study evaluating the drug in calcific aortic valve stenosis remains active. The residual pipeline is not trivial, Kisqali, Kesimpta, and Scemblix are compounding, but pelacarsen was supposed to open a new therapeutic category. Bank of America does not believe the result breaks the Novartis investment thesis and views the drug as representing only a small portion of its valuation. At current levels NVS trades at a material premium to its GF Value estimate, meaning the market was pricing in future pipeline success that is now partially gone.
Novo Nordisk. The damage runs deeper. Ziltivekimab failed ZEUS, and Novo has taken a DKK 4.6 billion non-cash impairment charge tied to ziltivekimab in Q3 2026. The company also moved to end the Phase 3 heart failure trials after a Data Monitoring Committee recommendation: HERMES is being closed, and ATHENA has discontinued study treatment and is completing as planned, with readouts expected in the first half of 2027. ARTEMIS, evaluating ziltivekimab in acute post-myocardial infarction patients, continues, with data expected in the first half of 2027. ARTEMIS tests the same IL-6 mechanism in an acute setting where IL-6 spikes sharply, distinct from the chronic low-grade inflammation addressed in ZEUS. That is the scientific rationale for hope, but it is a thin one after a clean null result. Heavy dependence on semaglutide and pipeline setbacks compound the risk.
The Wider Field
Amgen and Lilly have linked their siRNA candidates, olpasiran and lepodisiran, to deeper Lp(a) reductions than pelacarsen achieved. Analysts were looking to the pelacarsen data for signs that lowering Lp(a) more would drive better outcomes. Those signs were not there. Some analysts had identified any signal in the high-Lp(a) subgroup as a positive read-across for olpasiran and lepodisiran. Pelacarsen was equally ineffective in that subgroup as in the overall population.
Olpasiran and lepodisiran could still succeed where pelacarsen failed. Amgen and Lilly set higher Lp(a) thresholds for enrollment, 200 nmol/L and 175 nmol/L respectively, compared to roughly 149 nmol/L in Lp(a)HORIZON. Amgen has guided investors to an early-2028 timeframe for Phase 3 outcomes results for olpasiran, and Lilly’s Phase 3 program lists primary completion in March 2029. Both programs now carry a heavier burden of proof.
The pelacarsen news triggered declines in shares of both Novartis and partner Ionis Pharmaceuticals. The disappointing outcome removes momentum from an important partnered program and weakens a potential validation of Ionis’s antisense technology in Lp(a)-driven cardiovascular disease.
Bull / Base / Bear
Bull (NVS): Pelacarsen was a small valuation item. Rhapsido’s Phase 3 success in relapsing multiple sclerosis and Kisqali’s growth trajectory sustain the commercial story. BofA’s $185 target holds if immunology and neuroscience readouts deliver in the second half of 2026 and into 2027.
Base: NVS drifts 3-6% lower Monday as the market digests pelacarsen’s removal alongside the earlier del-desiran failure. NVO faces more persistent multiple compression given semaglutide concentration risk. Both stocks find support only if ARTEMIS data or external pipeline news creates a new catalyst.
Bear (NVO): Some analysts concluded after ZEUS that they now view it as unlikely the remaining ziltivekimab outcomes programs will read out positively. If ARTEMIS confirms the class effect is truly null in IL-6 inhibition, Novo loses its entire cardiovascular pipeline bet, acquired for $725 million from Corvidia in 2020, and is left fully dependent on a GLP-1 franchise facing intensifying Lilly competition with no near-term diversification.
The semaglutide concentration risk the bear case describes sits against a commercial backdrop that recently surprised to the upside. Novo’s Q3 results showed the Wegovy pill beating consensus by 17%, suggesting the GLP-1 franchise can still outrun the pipeline losses.
Bottom Line
The question markets are pricing this Monday is not whether pelacarsen or ziltivekimab can be salvaged. They cannot. The question is whether the biomarker-to-event translation problem revealed this weekend is drug-specific or target-specific. If Amgen’s olpasiran, with 95%-plus Lp(a) suppression and a higher-risk enrollment bar, cannot clear events either, the Lp(a) hypothesis fails at the class level. That verdict arrives in early 2028. Until then, Amgen shareholders are holding an open question that just got significantly harder to answer. For NVS, the thesis survives on its remaining portfolio. For NVO, the math requires Wegovy to do more work than any single product should have to carry.
